Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YOUNG KWANG CHAE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1598926107
CMS profile
208566
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$156,984.17

196 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $37,414.37 74
Genentech USA, Inc. $37,071.52 41
AstraZeneca Pharmaceuticals LP $25,665.36 23
Foundation Medicine, Inc. $23,330.00 13
E.R. Squibb & Sons, L.L.C. $17,339.52 20
F. Hoffmann-La Roche AG $6,338.09 9
PFIZER INC. $5,929.05 6
Merck Sharp & Dohme Corporation $3,707.33 7
Ipsen Biopharmaceuticals, Inc $188.42 2
Clovis Oncology, Inc. $0.51 1

Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YOUNG KWANG CHAE

NPI 1598926107 · CMS profile ID 208566

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598926107?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YOUNG KWANG CHAE, NPI 1598926107, CMS profile ID 208566. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598926107?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). YOUNG KWANG CHAE, NPI 1598926107, CMS profile ID 208566. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598926107?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
YOUNG KWANG CHAE, NPI 1598926107, CMS profile ID 208566, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1598926107?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

196 matching records · $156,984.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 196 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 196.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $6.1309/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695765095 CMS
Foundation Medicine, Inc. $2,500.0009/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675547825 CMS
Genentech USA, Inc. $71.6409/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681328307 CMS
AstraZeneca Pharmaceuticals LP $39.8209/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685378092 CMS
E.R. Squibb & Sons, L.L.C. $104.9309/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651392457 CMS
AstraZeneca Pharmaceuticals LP $29.7009/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685470607 CMS
Foundation Medicine, Inc. $1,165.0008/15/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675547823 CMS
Genentech USA, Inc. $24.2208/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681402965 CMS
Lilly USA, LLC $11.4207/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658231063 CMS
Lilly USA, LLC $29.0407/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658231955 CMS
Lilly USA, LLC $14.7107/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658232643 CMS
Lilly USA, LLC $82.0707/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658233873 CMS
Merck Sharp & Dohme Corporation $19.4607/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695908039 CMS
Genentech USA, Inc. $47.9407/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681340457 CMS
Genentech USA, Inc. $226.3907/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681357987 CMS
Genentech USA, Inc. $60.4707/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681366159 CMS
Genentech USA, Inc. $1,900.0007/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681370165 CMS
Genentech USA, Inc. $158.4607/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681375617 CMS
Foundation Medicine, Inc. $1,375.0007/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675547821 CMS
Genentech USA, Inc. $24.1307/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681403627 CMS
Genentech USA, Inc. $33.9107/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681406071 CMS
Ipsen Biopharmaceuticals, Inc $122.6707/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640624745 CMS
AstraZeneca Pharmaceuticals LP $19.1407/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685811493 CMS
AstraZeneca Pharmaceuticals LP $300.0007/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685140489 CMS
F. Hoffmann-La Roche AG $1,080.9406/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681075371 CMS
F. Hoffmann-La Roche AG $270.1006/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681075403 CMS
Foundation Medicine, Inc. $1,500.0006/19/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675547819 CMS
Lilly USA, LLC $2,450.0006/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658220993 CMS
Lilly USA, LLC $2,800.0006/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658220995 CMS
Lilly USA, LLC $2,800.0006/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658233333 CMS
Lilly USA, LLC $426.7706/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658220981 CMS
Lilly USA, LLC $577.2006/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658231055 CMS
Lilly USA, LLC $5.4306/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658231065 CMS
Lilly USA, LLC $77.5006/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658231067 CMS
Lilly USA, LLC $15.5006/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658231069 CMS
Lilly USA, LLC $453.4806/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658231949 CMS
Lilly USA, LLC $23.3005/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658224369 CMS
Lilly USA, LLC $16.0005/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658220983 CMS
Lilly USA, LLC $38.2205/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658227763 CMS
Lilly USA, LLC $16.4205/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658232639 CMS
Genentech USA, Inc. $2,600.0005/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681187085 CMS
Genentech USA, Inc. $120.1505/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681222299 CMS
Foundation Medicine, Inc. $1,375.0005/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675547817 CMS
Lilly USA, LLC $2,800.0005/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658231059 CMS
Lilly USA, LLC $1,750.0005/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658232637 CMS
Lilly USA, LLC $2,800.0005/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658224367 CMS
Lilly USA, LLC $2,450.0005/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658233869 CMS
Lilly USA, LLC $5.0605/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658220987 CMS
Lilly USA, LLC $63.2805/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658231061 CMS
Lilly USA, LLC $452.5005/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658232631 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $156,984.17 196
PY2020 $47,447.62 46
PY2021 $79,752.55 81
PY2022 $98,045.74 90
PY2023 $70,248.84 87
PY2024 $59,036.30 70
PY2025 $51,454.03 79

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $247,871.79 53
PY2024 Principal investigator $184,615.00 17
PY2023 Recipient $92.34 2
PY2023 Principal investigator $61,214.41 10
PY2022 Recipient $1,536.87 1
PY2022 Principal investigator $50,012.03 13
PY2021 Principal investigator $201,719.61 18
PY2020 Recipient $341.49 1
PY2020 Principal investigator $385,496.19 35
PY2019 Recipient $37.44 1
PY2019 Principal investigator $745,620.60 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,474.22 12/11/2025 Non-covered Recipient Entity
Northwestern University
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244047127
Principal investigator 1 Genentech, Inc. $3,595.00 11/06/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211631872
Principal investigator 1 Genentech, Inc. $1,000.00 11/06/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211631876
Principal investigator 1 ABBVIE INC. $325.00 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516807
Principal investigator 1 ABBVIE INC. $990.00 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516809
Principal investigator 1 ABBVIE INC. $7,590.00 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516811
Principal investigator 1 ABBVIE INC. $25,654.35 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516813
Principal investigator 1 ABBVIE INC. $3,300.00 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516815
Principal investigator 1 ABBVIE INC. $1,558.15 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516817
Principal investigator 1 ABBVIE INC. $2,005.08 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516827
Principal investigator 1 ABBVIE INC. $4,620.00 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516829
Principal investigator 1 ABBVIE INC. $2,341.68 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516831
Principal investigator 1 ABBVIE INC. $3,000.00 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516833
Principal investigator 1 ABBVIE INC. $2,640.00 10/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202516839
Principal investigator 1 Sumitomo Pharma America, Inc. $0.75 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647251
Principal investigator 1 Sumitomo Pharma America, Inc. $3.75 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647255
Principal investigator 1 Sumitomo Pharma America, Inc. $33.75 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647258
Principal investigator 1 Sumitomo Pharma America, Inc. $50.00 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647262
Principal investigator 1 Sumitomo Pharma America, Inc. $9.00 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647267
Principal investigator 1 Sumitomo Pharma America, Inc. $79.28 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647271
Principal investigator 1 Sumitomo Pharma America, Inc. $19.82 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647274
Principal investigator 1 Sumitomo Pharma America, Inc. $220.16 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647279
Principal investigator 1 Sumitomo Pharma America, Inc. $1.05 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647282
Principal investigator 1 Sumitomo Pharma America, Inc. $133.77 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647287
Principal investigator 1 Sumitomo Pharma America, Inc. $105.68 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647290
Principal investigator 1 Sumitomo Pharma America, Inc. $607.66 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647296
Principal investigator 1 Sumitomo Pharma America, Inc. $267.54 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647301
Principal investigator 1 Sumitomo Pharma America, Inc. $79.26 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647305
Principal investigator 1 Sumitomo Pharma America, Inc. $343.44 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647309
Principal investigator 1 Sumitomo Pharma America, Inc. $106.02 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647314
Principal investigator 1 Sumitomo Pharma America, Inc. $118.89 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647317
Principal investigator 1 Sumitomo Pharma America, Inc. $17.02 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF SMP-3124LP IN ADULTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1176647322
Principal investigator 1 Boehringer Ingelheim International GmbH $70,874.97 07/31/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220784407
Principal investigator 1 Boehringer Ingelheim International GmbH $9,129.09 06/30/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220784405
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $59.40 05/27/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220999097
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $221.54 05/27/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220999099
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 05/27/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220999101
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,204.50 05/27/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220999103
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $549.63 05/27/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220999105
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $66.00 05/27/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220999107
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $17.55 05/27/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220999109
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $64.80 05/27/2025 Non-covered Recipient Entity
NWN UNIV
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220999111
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,118.60 05/22/2025 Non-covered Recipient Entity
Northwestern University
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244047118
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $32,822.51 05/22/2025 Non-covered Recipient Entity
Northwestern University
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244047121
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,000.00 05/22/2025 Non-covered Recipient Entity
Northwestern University
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244047123
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,940.00 05/22/2025 Non-covered Recipient Entity
Northwestern University
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244047125
Principal investigator 1 Genentech, Inc. $1,500.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211631775
Principal investigator 1 Genentech, Inc. $22,933.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211631779
Principal investigator 1 Genentech, Inc. $1,500.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211631783
Principal investigator 1 Genentech, Inc. $2,700.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211631786
Principal investigator 1 Genentech, Inc. $5,160.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211631792
Principal investigator 1 Genentech, Inc. $13,000.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211631796
Principal investigator 1 Genentech, Inc. $2,600.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211631801